Raloxifene
Brand Names: Evista
Methodology & AI Transparency ⓘ
Raloxifene Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Raloxifene hydrochloride tablet, USP is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women.
- 2 Real-world patient consensus: Zero-PHI community consensus: 81% favorable across 7 logged regimens (Evista).
- 3 Typical cash cost range: Dispensing cost comparison spans $8.41 mail/discount cash up to $34.50 uninsured retail (federal NADAC $0.2205).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Raloxifene): arthralgia (5.3%), peripheral edema (4.6%), nausea (7.3%).
Ask our AI Specialists anything about Raloxifene
Raloxifene Mechanism, CYP450 Pathways & DailyMed Monograph
Raloxifene hydrochloride tablet, USP is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. (1.1) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. (1.2) . Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. (1.3) Important Limitations: Raloxifene hydrochloride is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer.
12.1 Mechanism of Action Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism). The agonistic or antagonistic action of raloxifene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promoters. Raloxifene appears to act as an estrogen agonist in bone.
Following administration (60 mg/1 Tablet), Raloxifene achieves Oral fraction absorbed ranges from 59% to 71% (Raloxifene 60) bioavailability and oral tmax achieved within 2 to 5 hours following raloxifene ingestion onset, governed by a Mean elimination half-life of 4 to 17 hours across adult Raloxifene dosing terminal half-life through dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of raloxifene.
Before initiating Raloxifene at 60 mg/1 Tablet, clinical safety checklists rule out active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.; contraindicated in patients with prior serious allergic response to raloxifene (ndc 60687-266). Logged tolerability patterns center on headache (7.6% of reports), nausea (7.3% of reports), dizziness (6.4% of reports).
Raloxifene may displace or alter hepatic clearance of warfarin; check baseline and post-titration INR.
Reconcile eGFR-adjusted medications before escalating Raloxifene in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
- Contraindicated in patients with prior serious allergic response to Raloxifene (NDC 60687-266)
Logged Side-Effect Incidence (7 Reports)
Raloxifene Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Raloxifene)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Prospective, randomized comparison between raloxifene and clomiphene citrate for No serious side effects were observed in either group. Fertility and sterility • 2011-09-15 • Randomized Controlled Trial | N = 82 | 88/100 | PMID 21782166 ↗ |
Raloxifene Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2205/unit (~$6.62/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $8.41 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $9.67 / mo | View logs ↓ |
| Midi Health Perimenopause & HRT Clinic (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $59.00 consult | Program details |
Raloxifene Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Raloxifene RxNorm Concept ID | 1490065 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2205 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $8.41 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 81.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Raloxifene Patient Community, Cohort Filters & Dosage Logs
Deterministic Raloxifene reference combining NIH RxNorm (1490065), Medicaid NADAC ($0.2205/unit), and anonymous cohort outcomes (81% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Raloxifene community threads and patient logs by age, biological sex, dosage, and treatment duration.